We can’t show the full text here under this license.
Heart attack and stroke rates in people starting SGLT2-inhibitors compared to other diabetes medicines in real-world care
Updated
Abstract
The study included 205,160 patients and reported that initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) was associated with lower rates of myocardial infarction and stroke compared to other glucose-lowering drugs.
- There were 1077 myocardial infarction events and 968 stroke events during the follow-up period.
- Initiation of SGLT-2i was associated with a hazard ratio of 0.85 for myocardial infarction compared to other glucose-lowering drugs.
- For stroke, the initiation of SGLT-2i was associated with a hazard ratio of 0.83.
- Statistical significance was found for both outcomes, with P-values of .05 for myocardial infarction and .02 for stroke.
- The findings support previous cardiovascular outcomes trials, indicating potential cardiovascular benefits of SGLT-2i.
Simplified
Key numbers
0.85
Lower Risk of Myocardial Infarction
Hazard ratio for MI in patients initiating SGLT-2i vs. oGLDs
0.83
Lower Risk of Stroke
Hazard ratio for stroke in patients initiating SGLT-2i vs. oGLDs
205160
205,160 Patients Analyzed
Total number of patients included in the analysis